Literature DB >> 17043116

Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.

Ronny Beer1, Klaus W Engelhardt, Bettina Pfausler, Gregor Broessner, Raimund Helbok, Peter Lackner, Christian Brenneis, Stefan T Kaehler, Apostolos Georgopoulos, Erich Schmutzhard.   

Abstract

The pharmacokinetic profile of linezolid in cerebrospinal fluid (CSF) in five neurointensive care patients with staphylococcal ventriculitis was studied. The mean area under concentration-time curve (+/- standard deviation) was 63 +/- 18.9 mg x h/liter, with a CSF-to-plasma ratio of 0.8 +/- 0.3. Times above MIC in CSF were 99.8% and 57.2% for pathogens with MICs of 2 mg/liter and 4 mg/liter, respectively.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17043116      PMCID： PMC1797655          DOI： 10.1128/AAC.00515-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections.

Authors:  P Villani; M B Regazzi; F Marubbi; P Viale; L Pagani; F Cristini; B Cadeo; G Carosi; R Bergomi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Authors:  J Albanèse; M Léone; B Bruguerolle; M L Ayem; B Lacarelle; C Martin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 3.  The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors:  K Hiramatsu; L Cui; M Kuroda; T Ito
Journal:  Trends Microbiol       Date:  2001-10       Impact factor: 17.079

4.  In vivo pharmacodynamics of a new oxazolidinone (linezolid).

Authors:  D Andes; M L van Ogtrop; J Peng; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Epidemiology, diagnosis, treatment, and prevention of cerebrospinal fluid shunt infections.

Authors:  R Bayston
Journal:  Neurosurg Clin N Am       Date:  2001-10       Impact factor: 2.509

6.  The efficacy and cost of prophylactic and perioprocedural antibiotics in patients with external ventricular drains.

Authors:  C H Alleyne; M Hassan; J M Zabramski
Journal:  Neurosurgery       Date:  2000-11       Impact factor: 4.654

7.  Linezolid for the treatment of central nervous system infections in neurosurgical patients.

Authors:  Pierluigi Viale; Leonardo Pagani; Francesco Cristini; Roberto Stefini; Riccardo Bergomi; Paolo Colombini; Giampiero Carosi
Journal:  Scand J Infect Dis       Date:  2002

Review 8.  Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.

Authors:  Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

9.  The impact of methicillin-resistant Staphylococcus aureus in a neurosurgical unit: a growing problem.

Authors:  Kanna K Gnanalingham; Ashraf Elsaghier; Christopher Kibbler; Colin Shieff
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

Review 10.  Ventriculostomy-related infections: a critical review of the literature.

Authors:  Alan P Lozier; Robert R Sciacca; Mario F Romagnoli; E Sander Connolly
Journal:  Neurosurgery       Date:  2002-07       Impact factor: 4.654
View more
  17 in total

1.  The Use of Daptomycin and Linezolid to Treat Vancomycin-Intermediate Staphylococcus haemolyticus Infection in a Premature Infant.

Authors:  Kalen B Porter; Bethany Lynch; Chitra S Mani
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

Review 2.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

3.  Neuroprotective potential of Linezolid: a quantitative and distribution study via mass spectrometry.

Authors:  Sooraj Baijnath; Adeola Shobo; Linda A Bester; Sanil D Singh; Gert Kruger; Per I Arvidsson; Tricia Naicker; Thavendran Govender
Journal:  J Mol Histol       Date:  2016-06-21       Impact factor: 2.611

4.  Action of linezolid or vancomycin on biofilms in ventriculoperitoneal shunts in vitro.

Authors:  Roger Bayston; Gautham Ullas; Waheed Ashraf
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

5.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

6.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

7.  Management of nosocomial external ventricular drain-related ventriculomeningitis.

Authors:  Ronny Beer; Bettina Pfausler; Erich Schmutzhard
Journal:  Neurocrit Care       Date:  2008-11-04       Impact factor: 3.210

8.  Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.

Authors:  Nuggehally R Srinivas; Muzeeb Syed
Journal:  Drugs R D       Date:  2016-03

Review 9.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.